[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549483":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":32,"locations":38,"responsibleParty":223,"collaborators":225,"id":228,"slug":229,"hasResults":230,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":11,"eligibilityCriteria":234,"healthyVolunteers":230,"sex":235,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":11,"studyType":241,"phases":242,"briefSummary":244,"conditions":245,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":256},{"fullName":5,"class":6},"Shanghai Jiaolian Drug Research and Development Co., Ltd","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"B013","EXPERIMENTAL",null,[13,14],"Drug: B013","Drug: Paclitaxel",{"label":16,"type":17,"description":11,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",[14,19],"Drug: Placebo",[21,25,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.",[9],{"type":22,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Paclitaxel","Paclitaxel: 80 mg\u002Fm\\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.",[9,16],{"type":22,"name":16,"description":30,"armGroupLabels":31,"otherNames":11},"Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.",[16],[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Xiaohua Wu","CONTACT","0086-021-64175590","JJYIN555@163.com",[39,54,65,76,87,98,109,117,128,139,149,157,168,179,190,201,212],{"facility":40,"status":41,"city":42,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Beijing Cancer Hospital","RECRUITING","Beijing","China","CN",{"type":46,"coordinates":47},"Point",[48,49],116.39723,39.9075,{"lat":49,"lon":48},[52],{"name":53,"role":35,"phone":11,"phoneExt":11,"email":11},"Hong Zheng",{"facility":55,"status":41,"city":56,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"The First Affiliated Hospital of Bengbu Medical University","Bengbu",{"type":46,"coordinates":58},[59,60],117.36083,32.94083,{"lat":60,"lon":59},[63],{"name":64,"role":35,"phone":11,"phoneExt":11,"email":11},"Hongli Liu",{"facility":66,"status":41,"city":67,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"XiangYa Hospital CentralSouth University","Changsha",{"type":46,"coordinates":69},[70,71],112.97087,28.19874,{"lat":71,"lon":70},[74],{"name":75,"role":35,"phone":11,"phoneExt":11,"email":11},"Yu Zhang",{"facility":77,"status":41,"city":78,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Fujian Cancer Hospital","Fuzhou",{"type":46,"coordinates":80},[81,82],119.30611,26.06139,{"lat":82,"lon":81},[85],{"name":86,"role":35,"phone":11,"phoneExt":11,"email":11},"Rong Xie",{"facility":88,"status":41,"city":89,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Sun Yat-sen Memorial Hospital, Sun Yat-sen University","Guangzhou",{"type":46,"coordinates":91},[92,93],113.25,23.11667,{"lat":93,"lon":92},[96],{"name":97,"role":35,"phone":11,"phoneExt":11,"email":11},"Qunxian Rao",{"facility":99,"status":41,"city":100,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Cancer Hospital of Shandong First Medical University","Jinan",{"type":46,"coordinates":102},[103,104],116.99722,36.66833,{"lat":104,"lon":103},[107],{"name":108,"role":35,"phone":11,"phoneExt":11,"email":11},"Liang Chen",{"facility":110,"status":41,"city":100,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},"Qilu Hospital of Shandong University",{"type":46,"coordinates":112},[103,104],{"lat":104,"lon":103},[115],{"name":116,"role":35,"phone":11,"phoneExt":11,"email":11},"Kun Song",{"facility":118,"status":41,"city":119,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Yunnan Cancer Hospital","Kunming",{"type":46,"coordinates":121},[122,123],102.71833,25.03889,{"lat":123,"lon":122},[126],{"name":127,"role":35,"phone":11,"phoneExt":11,"email":11},"Hongying Yang",{"facility":129,"status":41,"city":130,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Guangxi Medical University Cancer Hospital","Nanning",{"type":46,"coordinates":132},[133,134],108.31667,22.81667,{"lat":134,"lon":133},[137],{"name":138,"role":35,"phone":11,"phoneExt":11,"email":11},"He Wang",{"facility":140,"status":41,"city":141,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Fudan University Shanghai Cancer center","Shanghai",{"type":46,"coordinates":143},[144,145],121.45806,31.22222,{"lat":145,"lon":144},[148],{"name":34,"role":35,"phone":11,"phoneExt":11,"email":11},{"facility":150,"status":41,"city":141,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":151,"geoPoint":153,"contacts":154},"The Obstetrics & Gynecology Hospital of Fudan University",{"type":46,"coordinates":152},[144,145],{"lat":145,"lon":144},[155],{"name":156,"role":35,"phone":11,"phoneExt":11,"email":11},"Xin Lu",{"facility":158,"status":41,"city":159,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"The Second Hospital of Hebei Medical University","Shijiazhuang",{"type":46,"coordinates":161},[162,163],114.47861,38.04139,{"lat":163,"lon":162},[166],{"name":167,"role":35,"phone":11,"phoneExt":11,"email":11},"Xianghua Huang",{"facility":169,"status":41,"city":170,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan",{"type":46,"coordinates":172},[173,174],114.26667,30.58333,{"lat":174,"lon":173},[177],{"name":178,"role":35,"phone":11,"phoneExt":11,"email":11},"Guiling Li",{"facility":180,"status":41,"city":181,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"Shananxi Provincial Cancer Hospital","Xi'an",{"type":46,"coordinates":183},[184,185],108.92861,34.25833,{"lat":185,"lon":184},[188],{"name":189,"role":35,"phone":11,"phoneExt":11,"email":11},"Guoqing Wang",{"facility":191,"status":41,"city":192,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"The First Affiliated Hospital of Xiamen University","Xiamen",{"type":46,"coordinates":194},[195,196],118.08187,24.47979,{"lat":196,"lon":195},[199],{"name":200,"role":35,"phone":11,"phoneExt":11,"email":11},"Jianfa Lan",{"facility":202,"status":41,"city":203,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Yibin city second people's Hospital","Yibin",{"type":46,"coordinates":205},[206,207],104.63994,28.7593,{"lat":207,"lon":206},[210],{"name":211,"role":35,"phone":11,"phoneExt":11,"email":11},"Kaijian Lei",{"facility":213,"status":41,"city":214,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"Henan Cancer Hospital","Zhengzhou",{"type":46,"coordinates":216},[217,218],113.64861,34.75778,{"lat":218,"lon":217},[221],{"name":222,"role":35,"phone":11,"phoneExt":11,"email":11},"Yanlin Luo",{"type":224,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[226],{"name":227,"class":6},"Shanghai Pharmaceuticals Holding Co., Ltd","100549483","phase-2-a-study-of-b013-in-combination-with-paclitaxel-in-patients-with-platinum-resistant-recurrent-ovarian-cancer-100549483",false,"NCT06434610","A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.","Inclusion Criteria:\n\n1. Subjects who voluntarily participate in this study and sign informed consent form;\n2. Ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by histopathological examination and meeting the criteria for platinum resistance recurrence;\n3. ECOG performance status of 0 or 1；\n4. Expected survival \\> 12 weeks;\n5. The subject has at least one measurable lesion;\n6. Normal function of major organs;\n7. The fertile subjects agree to use reliable contraception from signing the informed consent to at least 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Subjects who have received prescribed treatment previously;\n2. Subjects who are still using anti-tumor traditional Chinese patent medicines at the time of signing informed consent;\n3. Subjects with known central nervous system metastasis and multiple bone metastasis;\n4. Subjects who had clinical symptoms of pleural effusion, pericardial effusion or ascites before randomization and needed puncture drainage, or had received puncture drainage within the previous 2 weeks;\n5. Have a history of other malignant tumors within 5 years before signing the informed consent;\n6. Subjects with prescribed cardiovascular diseases;\n7. Subjects with infections requiring intravenous antibiotic infusion within 2 weeks prior to randomization;\n8. Had severe lung disease before randomization;\n9. Before randomization, the peripheral nerve toxicity of previous anti-tumor treatment was \\> grade 2, and other reversible toxicity was \\> grade 1;\n10. Subjects who had undergone surgery within 28 days prior to randomization and did not recover from adverse effects of surgery;\n11. Subjects who participated in clinical trials within 30 days prior to randomization and received other unmarketed investigational drugs;\n12. Subjects who are known to be allergic to any component of B013 or paclitaxel.\n13. Subjects with a known history of substance abuse, alcohol or drug use; Subjects with a known history of neurological or psychiatric disorders;\n14. Female subjects who are pregnant or breastfeeding;\n15. Other situations determined by the researchers and\u002For sponsors as unsuitable for participation in this trial.","FEMALE","18 Years","75 Years",{"count":239,"type":240},90,"ESTIMATED","INTERVENTIONAL",[243],"PHASE2","To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.",[246],"Platinum-resistant Recurrent Ovarian Cancer","2026-04-29",{"date":249,"type":250},"2026-05-05","ACTUAL",{"date":252,"type":250},"2024-07-11",{"date":254,"type":240},"2026-12-31",{"name":5,"class":6},17]